NRG Oncology Network Group Operations Center

NRG管理核心摘要 NRG肿瘤学（NRG）行政核心提供领导和基础设施 支持NCI成人组中最大的临床试验组合所必需的 国家临床试验网络（NCTN），成员包括220多个主要成员 研究中心-包括几乎所有的领先学术参与研究中心（LAPS）和一个强大的 为NCTN的整体管理和成功做出贡献。NRG利用高度 成功的多PI模型提供了非常有能力的领导和科学监督， 充满活力的委员会领导和指导，知识渊博，经验丰富的行政 和业务领导，以及适当的相关支持。NRG，一个只有四个人组成的团体 几年前，它利用其传统团体的优势，形成了一个综合的、现代的 针对NCTN内特定人群的临床试验组织。值得注意的是 即使在三家公司合并的过程中，NRG在所有领域都保持了很高的生产力 传统团体，证明了NRG的卓越领导和周到的 组织结构到位。除了支持自己的目标，NRG是一个高度 NCTN的合作成员。NRG与其他团体共同领导了一些试验， 支持其他团体的16项研究，参加了许多NCI任命的 指导委员会、工作组和工作队，并领导了新的远程 监测标准。NRG拥有适当的领导和基础设施，可以继续支持 临床试验和会员目标，并继续作为参与的利益相关者， NCTN的整体管理和成功。

NRG Administrative Core Abstract The NRG Oncology (NRG) Administrative Core provides the leadership and infrastructure necessary to support the largest portfolio of clinical trials among the adult groups in the NCI National Clinical Trail Network (NCTN), a membership encompassing over 220 main member sites – including nearly every Lead Academic Participating Site (LAPS) and a robust contribution to the overall management and success of the NCTN. NRG utilizes a highly successful multiple-PI model to provide remarkably capable leadership and scientific oversight, dynamic committee leadership and mentoring, knowledgeable and experienced administrative and operational leadership, and appropriate associated support. NRG, a group formed only four years ago, has leveraged the strengths of its legacy groups to form an integrated, modern clinical trials organization addressing specific populations within the NCTN. It is notable that NRG remained highly productive in all realms even while navigating the merger of the three legacy groups, a testament to the remarkable leadership of NRG and the thoughtful organizational structure put into place. In addition to supporting its own goals, NRG is a highly collaborative member of the NCTN. NRG co-led a number of trials with other groups, championed sixteen studies from other groups, participated in numerous NCI-appointed steering committees, workgroups, and task forces, and led the development of new remote monitoring standards. NRG has the leadership and infrastructure in place to continue to support the clinical trial and membership goals as well as continue to serve as engaged stakeholders in the overall management and success of the NCTN.